S
Shawn Egri
Researcher at Broad Institute
Publications - 12
Citations - 298
Shawn Egri is an academic researcher from Broad Institute. The author has contributed to research in topics: Histone & Chromatin. The author has an hindex of 5, co-authored 12 publications receiving 197 citations.
Papers
More filters
Journal ArticleDOI
KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance
Kunihiko Hinohara,Hua-Jun Wu,Sébastien Vigneau,Thomas O. McDonald,Kyomi J. Igarashi,Kimiyo N. Yamamoto,Thomas Madsen,Anne Fassl,Shawn Egri,Malvina Papanastasiou,Lina Ding,Guillermo Peluffo,Ofir Cohen,Stephen C. Kales,Madhu Lal-Nag,Ganesha Rai,David J. Maloney,Ajit Jadhav,Anton Simeonov,Nikhil Wagle,Myles Brown,Alexander Meissner,Piotr Sicinski,Jacob D. Jaffe,Rinath Jeselsohn,Alexander A. Gimelbrant,Franziska Michor,Kornelia Polyak +27 more
TL;DR: It is shown that genetic deletion of KDM5A/B or inhibition of K DM5 activity increases sensitivity to anti-estrogens by modulating estrogen receptor (ER) signaling and by decreasing cellular transcriptomic heterogeneity.
Journal ArticleDOI
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations.
Lev Litichevskiy,Ryan Peckner,Jennifer G. Abelin,Jacob K. Asiedu,Amanda L. Creech,John F. Davis,Desiree Davison,Caitlin M. Dunning,Jarrett D. Egertson,Shawn Egri,Joshua Gould,Tak Ko,Sarah A. Johnson,David L. Lahr,Daniel D. Lam,Zihan Liu,Nicholas J. Lyons,Xiaodong Lu,Brendan MacLean,Alison E. Mungenast,Adam Officer,Ted Natoli,Malvina Papanastasiou,Jinal Patel,Vagisha Sharma,Courtney Toder,Andrew A. Tubelli,Jennie Z. Young,Steven A. Carr,Todd R. Golub,Aravind Subramanian,Michael J. MacCoss,Li-Huei Tsai,Jacob D. Jaffe +33 more
TL;DR: A systematic library resource of proteomic signatures that measure changes in the reduced-representation phosphoproteome (P100) and changes in epigenetic marks on histones (GCP) is presented and consistent connectivity among cell types revealed cellular responses that transcended lineage and unexpected associations between drugs.
Journal ArticleDOI
Study of mitotic chromatin supports a model of bookmarking by histone modifications and reveals nucleosome deposition patterns.
Elisheva Javasky,Inbal Shamir,Shashi Gandhi,Shawn Egri,Oded Sandler,Scott B. Rothbart,Noam Kaplan,Jacob D. Jaffe,Alon Goren,Alon Goren,Itamar Simon +10 more
TL;DR: Evidence is provided to support a model where histone modifications may play a role in mitotic bookmarking and uncovers new insights into the deposition of nucleosomes during mitosis.
Posted ContentDOI
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations
Lev Litichevskiy,Ryan Peckner,Jennifer G. Abelin,Jacob K. Asiedu,Amanda L. Creech,John F. Davis,Desiree Davison,Caitlin M. Dunning,Jarrett D. Egertson,Shawn Egri,Joshua Gould,Tak Ko,Sarah A. Johnson,David L. Lahr,Daniel D. Lam,Zihan Liu,Nicholas J. Lyons,Xiaodong Lu,Brendan MacLean,Alison E. Mungenast,Adam Officer,Ted Natoli,Malvina Papanastasiou,Jinal Patel,Vagisha Sharma,Courtney Toder,Andrew A. Tubelli,Jennie Z. Young,Steven A. Carr,Todd R. Golub,Aravind Subramanian,Michael J. MacCoss,Li-Huei Tsai,Jacob D. Jaffe +33 more
TL;DR: First-of-its-kind public resource of proteomic responses to systematically administered perturbagens demonstrated, which could be leveraged against public domain external datasets to recognize therapeutic hypotheses that are consistent with ongoing clinical trials for the treatment of multiple myeloma and acute lymphocytic leukemia.
Journal ArticleDOI
A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML.
Srila Gopal,Qing Lu,Joshua J. Man,Wendy Baur,Sitara P. Rao,Lev Litichevskiy,Malvina Papanastasiou,Amanda L. Creech,Katherine C. DeRuff,James Mullahoo,Adam Officer,Shawn Egri,Desiree Davison,Jacob D. Jaffe,Iris Z. Jaffe +14 more
TL;DR: This phosphoproteomic EC toxicity signature predicts bosutinib to be safe, providing a potential screening tool for safer drug development.